中医药现代化研究20年回顾与展望(4)
[7] Phase III trial of Dantonic(T89) capsule to prevent and treat stable angina (CAESA)[EB/OL]. 2015-05-19. https：//www. clinicaltrials. gov/ct2/show/NCT01659580？term=tasly&rank=3.
[8] Efficacy and safety study of lipid-lowering effects of Xuezhikang (XZK) in patients with hyperlipidemia[EB/OL]. 2014-07-22. https：//www. clinicaltrials. gov/ct2/show/NCT01327014？term=NCT01327014&rank=1.
[9] Assess the antifibrotic activity of Fuzheng Huayu in chronic hepatitis C patients with hepatic fibrosis[EB/OL]. 2014-06-18. https：//www. clinicaltrials. gov/ct2/show/NCT00854087？term=NCT00854087&rank=1.
[10] Safety and exploratory efficacy of Kanglaite injection in pancreatic cancer[EB/OL]. 2015-06-17. https：//www. clinicaltrials. gov/ct2/show/NCT00733850？term=NCT00733850&rank=1.
[11] 国务院办公厅. 国务院办公厅关于印发中医药健康服务发展规划(2015—2020年)的通知[EB/OL]. 2015-05-07. http：//www. gov. cn/zhengce/content/2015-05/07/content_9704. htm.
[责任编辑 马超一] (张伯礼 张俊华)
[8] Efficacy and safety study of lipid-lowering effects of Xuezhikang (XZK) in patients with hyperlipidemia[EB/OL]. 2014-07-22. https：//www. clinicaltrials. gov/ct2/show/NCT01327014？term=NCT01327014&rank=1.
[9] Assess the antifibrotic activity of Fuzheng Huayu in chronic hepatitis C patients with hepatic fibrosis[EB/OL]. 2014-06-18. https：//www. clinicaltrials. gov/ct2/show/NCT00854087？term=NCT00854087&rank=1.
[10] Safety and exploratory efficacy of Kanglaite injection in pancreatic cancer[EB/OL]. 2015-06-17. https：//www. clinicaltrials. gov/ct2/show/NCT00733850？term=NCT00733850&rank=1.
[11] 国务院办公厅. 国务院办公厅关于印发中医药健康服务发展规划(2015—2020年)的通知[EB/OL]. 2015-05-07. http：//www. gov. cn/zhengce/content/2015-05/07/content_9704. htm.
[责任编辑 马超一] (张伯礼 张俊华)